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Abstract 
Primary hyperparathyroidism is an endocrine disorder that results in overproduction of parathyroid hormone by overactivated para-
thyroid gland leading to a significant rise in blood serum calcium. It results in hypercalcaemia, which has a significant impact mainly 
on the kidneys and bones and results in a variety of signs and symptoms. Primary hyperparathyroidism should be treated because, if 
left without any therapy, it can lead even to death. Surgery is considered as the best and only successful therapy, with very low risk of 
recurrence and relatively low complication rate. The aim of this review is to present clinical basis, aetiology, diagnostic possibilities, and 
treatment opportunities. (Endokrynol Pol 2020; 71 (3): 260–189)
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Introduction 
Primary hyperparathyroidism (PHPT) is a gener-
alised endocrine disorder that leads to disturbances 
in the metabolism of calcium and phosphate due to 
an increase in autonomous production and secretion 
of parathyroid hormone by parathyroid glands. This 
excessive endocrine action usually results in hypercal-
caemia and hypophosphataemia as well as significantly 
elevated concentration of PTH in serum is significantly 
elevated [1]. The prevalence of PHPT ranges between 
0.1 and 1.0%, which makes it one of the most com-
mon endocrine disorders, directly after diabetes and 
thyroid gland diseases [2, 3]. It affects significantly 
more females than males [1]. The overall incidence 
is approximately one case per 1000 per year in men 
over the age of 60 and two cases per 1000 in women 
over 60 years of age. There are several aetiologies 
of PHPT. In fact, many cases (95%) are termed to be 
sporadic, where the most common underlying cause 
is solitary adenoma, which comprises about 84% of 
cases; double adenoma together with hyperplasia of 
all glands is present in approximately 15% of cases 
[1, 3]. The remaining 1% of cases comprise very rare 
cases of parathyroid carcinoma [1]. Multiple endocrine 
neoplasia type 1 (MEN1) and type 2A (MEN2A) is 
responsible for around 5% of all PHPT occurrence, 
which may occur in a familial pattern with no other 
endocrine abnormality already diagnosed. The aim of 
this work is to focus on and review the aetiology of 
PHPT. The clinical presentation of PHPT is highly vari-
able. Multiple signs and symptoms may be presented 
by the patient, such as nephrolithiasis, peptic ulcers, 
and increased resorption of bone [1]. However, even 
in patients who have not developed any of these, 
screening tests such as blood calcium level raise aware-
ness of the disease and lead to correct diagnosis. Due 
to such common incidence of this disease, there are 
already several known risk factors attributing to PHPT, 
such as lithium used to treat mental disorders over 
a prolonged period of time [1, 2]. Additionally, those 
patients who were irradiated externally or internally 
with isotopes of iodine presented greater risks towards 
this disease [1, 4]. Because tumours are responsible for 
most cases, the underlying cause of PHPT has to arise 
from abnormalities in genetics, more precisely from 
disturbances in the balance between proto-oncogenes, 
growth factor genes, and tumour suppressor genes. Is 
documented that sporadic and familial tumours are 
closely associated with defects in HPRT and MEN1 
genes [64].
Aetiology 
Solitary adenomas are responsible for approximately 
85% of all cases of PHPT. In 15% of them, hyperpla-
sia affects all glands with the main predisposition to 
chief cells. In very rare cases, adenomas may be found 
in more than one gland, with preservation of other, 
healthy glands [1]. However, in each case, resection 
of the affected gland is the best form of curing the 
disease. A normal parathyroid gland is the size of 
Endokrynologia Polska
DOI: 10.5603/EP.a2020.0027
Volume/Tom 71; Number/Numer 3/2020
ISSN 0423–104X
Grzegorz J. Kowalski, Department of General and Endocrine Surgery, Faculty of Medical Sciences in Zabrze,  
Medical University of Silesia, Katowice, Poland; e-mail: kowalskigrzeg@gmail.com
261
Endokrynologia Polska 2020; 71 (3)
R
E
V
IE
W
tumours of thyroid and adrenal medulla are not 
found in MEN1 [1].
Signs and symptoms
Currently, half or more patients with hyperparathyroid-
ism are asymptomatic, and specific signs and symptoms 
occur primarily in the kidneys in the form of stones, as 
well as bone diseases. Nowadays the frequency of de-
tection of asymptomatic cases has increased, mainly due 
to routine biochemical tests done for other purposes, so 
the incidence of renal complications is lower. Normal 
cellular function depends on calcium homeostasis, 
and in PHPT it is disrupted. This results in manifesta-
tions such as urinary, musculoskeletal, gastrointestinal, 
cardiovascular, neuromuscular, and neuropsychiatric 
symptoms [1]. The kidney involvement is mainly due 
to deposits of calcium, leading to nephrolithiasis in 
renal parenchyma and hypercalciuria [5]. Renal stones 
are mainly composed of calcium oxalate and calcium 
phosphate and may lead to urinary tract obstruction 
or infection, which results in loss of physiological renal 
functions. Nephrolithiasis is found in about 20% of 
PHPT cases, and its number is still increasing [6]. In 
increased parathormone production, calcium, which 
needs to be filtered, exceeds the renal tubules capacity 
of possible reabsorption and results in hypercalciuria 
in about 40% of patients [3]. On the other hand, neph-
rocalcinosis leads to phosphate retention and results in 
a significant decrease of urinary system functions. Usu-
ally it is hard to find both conditions in the same patient, 
so diagnosis must be made carefully. Hypercalcaemia 
manifests in the musculoskeletal system. There may 
also be a direct effect of PTH on bones because this 
hormone acts on osteoblast receptors, stimulating them 
to differentiate into osteoclasts, and hence leading to 
cortical bone resorption [7]. If the level of parathor-
mone is chronically increased, it causes osteoporosis, 
osteopaenia, or fibrosis [5]. The unique form of bone 
involvement in hyperparathyroidism is osteitis fibrosa 
cystica, which has several specific histological findings 
in microscopic examination, such as a reduction in the 
number of trabeculae and an increase in the amount of 
giant multinucleated osteoclasts on the bone surface. 
Fibrous tissues that have replaced physiological bone 
marrow elements can also be observed. Because osteo-
porosis and osteopaenia are understood as the most 
common diseases closely related to PHPT, osteitis fibrosa 
cystica is less common, and its reduced frequency has 
been not yet explained [1]. Manifestations of PHPT in 
CNS vary from moderate disturbances of personality to 
very severe mental disorders, including consciousness 
impairment, e.g. coma. Many patients suffering from 
PHPT have nonspecific symptoms including fatigue, 
an apple seed and weighs approximately 0.5 g. Mi-
croadenomas are defined as tumours that weigh less 
than less than 0.1 g, while a giant adenoma is over 2 
g. Adenomas usually are found within inferior para-
thyroid glands and are up to 1g in weight, but there 
are cases in which the neoplasm reaches the weight 
of a normal healthy parathyroid gland, i.e. 25 g [1, 
59, 60]. The establishment of distinction between hy-
perplasia and adenoma may be problematic. Where 
there is hyperplasia, the glands that are involved are 
sometimes so enlarged and asymmetric that they are 
normal in gross appearance. In such cases, a biopsy 
taken by the surgeon during the surgery is essential 
for interpreting findings and gross interpretation, 
because microscopic histological examination divulges 
the uniform pattern of chief cells and disappearance of 
fat [1]. If adenoma is present, there are normal glands 
present with physiological distribution and content of 
all the cells as well as fat [1]. Parathyroid carcinoma 
accounts for around 1% of PHPT cases and is usually 
not considered to be aggressive. If resection of the 
entire gland without rupture of the capsule is per-
formed as soon as possible, long-term survival without 
reccurrence is very likely, but still there are cases of 
relapse. On the other hand, even if the recrudescent 
parathyroid gland carcinoma grows, it is a very slow 
process that usually spreads within the neck. In such 
cases, again surgical resection may be manageable. 
Such a carcinoma may be aggressive and is likely to 
form metastases in lung, liver, and bones, which may 
be found during the initial operation [1]. However, it 
is hard for a surgeon to decide if the tumour is actu-
ally carcinoma and to eventually distinguish it from 
other forms of primary hyperparathyroidism. The 
potential diagnostic clue is measuring the degree of 
calcium elevation, where, in the case of carcinoma, it 
equals around 14 mg.
Hyperparathyroidism can occur in patients with-
out other endocrine disease in a familial pattern. 
There are few syndromes of multiple endocrine neo-
plasia (MEN), predominantly type 1 and type 2. Type 
1 disorder (MEN1) is also called Wermer ’s syndrome 
and appears as hyperparathyroidism together with 
tumours of the pituitary gland or pancreas. It may 
also be connected with Zollinger-Ellison syndrome 
due to the occurrence of peptic ulcers and gastric acid 
over secretion in such patients [1]. Type 2 disorder 
(MEN2) is another endocrine constellation, with auto-
somal dominant pattern of inheritance, and is closely 
associated with medullary carcinoma of the thyroid 
as well as with pheochromocytoma. Tumours associ-
ated with the type of multiple endocrine neoplasia 
are useful for distinction because pituitary gland or 
pancreatic tumours will not appear in MEN2, e.g. 
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disorders of circadian rhythm, mood depression, inabil-
ity to focus, concentrate, and memorise, and a decrease 
in creativity. It is so general that it cannot be considered 
as a clear indication for parathyroidectomy, especially 
because the third workshop from 2008 showed that 
in PHPT the presentation of psychological disorders 
is quite common, but the precise extent of neuropsy-
chiatric symptoms is not clear [1, 8]. Neuromuscular 
disorders in PHPT are directly connected with muscle 
weakness (especially peripheral), general fatigue, and 
marked muscle atrophy. Hence, the electromyogram 
tends to be within normal range and atrophic muscle 
fibres are without pathological changes. After surgical 
excision of parathyroid glands, atrophy may be totally 
reversed without any longer striking [1]. The group of 
subtle manifestations of PHPT includes gastrointestinal 
problems such as abdominal pain, and stomach and 
pancreas function disorders [1]. In addition, patients 
complain of nausea, vomiting, and constipation, and 
there are rare cases of acute pancreatitis [9]. There is 
also a marked increased tendency of duodenal ulcer 
occurrence. In patients suffering from MEN1 type 
of hyperparathyroidism, duodenal ulcers are result-
ing from associated tumours of the pancreas that are 
actively secreting increased amounts of gastrin [1]. In 
addition to these main findings, there have been recent 
studies showing a direct connection between PHPT 
and the cardiovascular system, such as calcification 
of valves and certain areas of myocardium. Moreover, 
lipid abnormalities resulting in arterial hypertension 
and coronary artery disease, hypertrophy of left ven-
tricle, and disturbances of conduction also occur [6]. In 
some cases, patients with PHPT present a parathyroid 
crisis because of increased concentration of calcium in 
serum. They are significantly dehydrated, which leads 
to an even greater increase in blood calcium levels. Such 
a condition is so dangerous because patients may have 
manifest disruption of cardiac and kidney functions, 
deterioration of central nervous system (CNS), and 
gastrointestinal disturbances in the form of nausea and 
vomiting connected with abdominal pain [10].
Diagnosis
Proper anamnesis
The first step in indicating the disease is to form a dif-
ferential diagnosis, which is made of: PHPT, lithium 
drug therapy, malignancies, increased calcium intake 
or reduction in excretion, excess of vitamin D, long 
immobilisation of the patient, hyperthyroidism, and 
multiple myeloma [11]. As neoplasm or malignancy 
stands for the most common cause of hypercalcaemia, 
PHPT is highly probable [12]. In such conditions, hyper-
calcaemia associated with PHPT is related to suppressed 
PTH levels because the negative feedback mechanism 
is still intact in parathyroid glands [5]. At the beginning 
of the diagnostic process of PHPT it is highly relevant 
to collect the family history with a focus on the clinical 
grounds described previously. The correct anamnesis 
can give a chance to confirm or exclude PHPT forms 
which are hereditary, particularly MEN 1 and 2 types. If 
the family history of PHPT is positive, genetic testing 
should be considered, especially in the diagnosis of 
patients younger than 50 years old [13]. After the fam-
ily anamnesis, the drug history should be made with 
emphasis on past or current usage of medicaments such 
as diuretics, which can raise the calcium level in blood 
serum without PHPT, as well as lithium, which is used 
to treat mental disorders such as depression. It is rel-
evant because long-term ingestion of those substances 
is thought to be closely associated with development 
of PHPT [1, 13].
Biochemical testing
The biochemical tests are very useful in the diagnosis of 
PHPT because they allow one to mark the hypercalcae-
mia that is caused by increased secretion of PTH from 
parathyroid glands [1]. For this aim, immunoassays are 
also used, but there are problems occurring with the 
interpretation of such results. Characteristically, the 
immunoreactive PTH level can be elevated or inap-
propriately normal [1]. The diagnosis is classical if the 
calcium is elevated when the concentration of PTH is 
also increased [13]. Sometimes it happens that mild 
PHPT occurs with PTH or calcium in blood serum is 
normal by laboratory means, so there appears a need for 
comparison of both values together, which will lead to 
a biochemically abnormal result [5]. The PHPT is called 
normal calcaemic when PTH is high and serum calcium 
level seems to be normal. However, inappropriate secre-
tion of PTH is found in patients with hypercalcaemia 
and inappropriately normal or unsuppressed PTH 
level [1]. Physiologically, when hypercalcaemia occurs, 
it should result in the activation of a negative feedback 
process acting directly on parathyroid glands, leading to 
suppression of PTH secretion. That implies that PHPT 
should be diagnosed even with normal levels of PTH 
in the serum when hypercalcaemia was detected. The 
comparison of found values is summarised in Table 1. 
There are some different reported opinions explaining 
the normocalcaemic variety of PHPT, showing that 
some surgeons assume that it may be a classical PHPT 
caused by disturbances in PTH secretion regulation, 
while others surmise the resistance to the action of this 
hormone [14].
Hypercalciuria is often found in hyperparathyroid-
ism; nevertheless, parathormone decreases calcium 
clearance so that excretion of calcium in urine (daily) 
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is lower than in patients in which hypercalcaemia 
was found, which was caused by a reason other than 
parathyroid gland disorders [1]. Primary hyperparathy-
roidism is not only associated with disorders of calcium 
metabolism; hence, in blood serum of patients, the 
phosphate level is usually low. However, there are cases 
of patients with already developed renal failure and 
normal phosphate levels. Hypophosphataemia is not 
as significant a diagnostic measure as hypercalcaemia 
because levels of phosphates are influenced by daily 
dietary intake and variations in diuresis, so the best time 
for sampling is in the morning. Nevertheless, patients 
who are suffering from severe hypercalcaemia may 
have decreased blood serum phosphate level (1). As-
sessing the response of blood serum calcium to admin-
istration of glucocorticoid drugs is a useful diagnostic 
criterion. It allows to differentiate the hypercalcaemia 
in PHPT from hypercalcaemia associated with other 
diseases, among which are: sarcoidosis, vitamin D in-
toxication, multiple myeloma, neoplasms, and carcino-
mas. In hyperparathyroidism, administration of 100 mg 
per day for around 10 days do not result in lowering 
the calcium levels unlike in other diseases related to 
hypercalcemia [1]. There are many tests to establish the 
function of parathyroid glands. Those are based on the 
effects of this hormone on renal action with phosphate; 
in particular, parathormone successfully decreases renal 
phosphate resorption. The clearance of phosphate can 
be determined by a standard technique within one- and 
two-hour intervals. Normal clearance of phosphate is 
about 10.8 ml per minute, while if the value reaches 
50% to 60%, it may indicate hyperparathyroidism, 
compared to normal values of phosphate resorption, 
where it reaches about 80%. Moreover, the possibility 
to measure nephrogenous cAMP is also appropriable 
in the diagnostics of PHPT [1].
Molecular testing
Every neoplastic change within the organism results 
from disturbance of equilibrium maintenance between 
proto-oncogenes and tumour suppressor genes. Ad-
ditionally, several other defective transmission mecha-
nisms have been described, such as cell cycle regulation 
or apoptosis induction [15]. The vast majority of primary 
hyperparathyroidism cases are caused by hyperplasia 
and further differentiation of modified cells, so genetic 
laboratory testing, which is more and more available, 
plays an essential role in prevention, diagnostics, and 
classification of tumours.  Sporadic PHPT, as mentioned 
before, stands for up to 95% of all PHPT cases. Al-
though it is so widespread, the exact causative genetic 
mutations are not well understood. Nevertheless, in 
sporadic PHPT, there are two genes closely linked to 
parathyroid adenomas such as: oncosuppressor gene 
MEN1 and cyclin D1 gene, which are located on the 
11th chromosome. In around 30% of sporadic parathy-
roid tumours, the homozygous loss of MEN1 locus has 
been found, so it is the major genetic somatic cause in 
sporadic PHPT [16]. On the other hand, overexpres-
sion of cyclin D1 has been associated with up to 40% 
of sporadic adenomas and around 90% of carcinomas 
[17]. Recently, a study confirmed MEN1 mutation and 
evaluated additional HRPT2 gene mutation associated 
with development of large parathyroid adenoma (LPA). 
In the majority of tumours, the observation brought 
total or partial loss of parafibromin expression, and in 
some of them loss of APC gene expression was found 
[18]. Negative parafibromin staining indicated a higher 
risk of recurrence/metastasis and mortality. The im-
munohistochemical staining of parafibromin seems to 
be more promising in predicting outcomes for patients 
with parathyroid carcinoma. Ki-67 antigen often cor-
relates with the course of cancer, which is also of great 
prognostic value in these diseases. Positive response to 
the presence of Ki-67 is more common in parathyroid 
cancer compared to benign lesions [61]. Nevertheless, 
cases taken into consideration were a result of the Array 
Comparative Genomic Hybridisation (aCGH) method, 
which has showed recurrent copy number alterations 
most frequently involving loss in 1p (29%), gain in 5 
(38%), and loss in 11q (33%). Another study points out 
that while bi-allelic inactivation of CDC73/HRPT2 seems 
unique to parathyroid malignancy, aberrant activation 
of cyclin D1 and Wnt/-catenin signalling has been re-
ported in benign and malignant parathyroid tumours 
(19). A different study [20] showed the importance of 
parathormone gene mRNA studying. All of the inves-
tigated cases were positive by PTH-PCR, which was 
confirmed by histological investigation – it led to the 
conclusion that reverse transcriptase-polymerase chain 
reaction (RT-PCR) detection of parathormone (PTH) 
gene mRNA in needle aspirates is a very useful method 
for parathyroid adenoma diagnosis. Parathyroid carci-
noma is one of the most malignant neoplastic changes 
of parathyroid glands; thus, the molecular changes 
have been studied in order to better understand the 
disease itself and to create the best therapy. A study 
Table 1. Clinical presentation in hyperparathyroidism. 
Based on [66]
Classical presentation Calcium PTH
Classical PHPT Increased Increased
Inappropriate secretion 
of PTH Increased
Within normal 
range
Normocalcaemic PHPT Within normal range Increased
PTH — parathormone; PHTP — primary hyperparathyroidism
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(21) evaluated tumour-specific genetic changes using 
next-generation sequencing (NGS), resulting in the 
conclusion that the most common genetic alterations 
were found within two pathways: the PI3K and TP53 
pathways, which leads to the conclusion that this 
method is also very helpful, and more studies based 
on those pathways should be taken into consideration. 
Molecular allelotyping was performed and described 
in our recent study. Polymorphic microsatellite markers 
were used, leading to the conclusion that parathyroid 
carcinomas develop de novo rather than from previ-
ously existing parathyroid adenomas [22]. Mutations 
that cause to primary hyperparathyroidism should 
be detected if multiple endocrine neoplasia type  1 
(MEN 1) is considered as the diagnosis. This disease 
is autosomal dominant in its inheritance pattern. The 
responsible mutation occurs in oncosuppressor gene 
MEN1 encoding protein menin, which negatively 
regulates progression of cell cycle, controls integrity of 
DNA, and partially regulates the process of apoptosis. In 
advanced diagnostics, the MEN1 test is advised. The 
positive result leads to the performance of a thymec-
tomy with parathyroid intervention as a prophylaxis 
in order to prevent the thymic carcinoids. If the MEN1 
test is negative, surgical intervention is needed but 
restricted to parathyroid glands that are hyperplastic 
or adenomatous [16]. Multiple endocrine neoplasia 
type 2 and genetic mutation leading to this disorder 
have also been described in different studies. Among 
the two variants, MEN2A is responsible for up to 80% 
of MEN2 syndromes. MEN2A syndrome is composed 
of hyperparathyroidism, hyperplasia of parathyroids, 
pheochromocytomas and medullary carcinoma [23]. 
Within those patients PHPT occurs in around 25% of 
MEN2A cases, usually after 30 years of life, and usually 
without any clinical symptoms. PHPT that is related 
to MEN2A may range from single parathyroid gland 
adenoma to multiglandular hyperplastic changes [16]. 
MEN2 syndrome is inherited in an autosomal domi-
nant pattern [24]. The proto-oncogene RET is the one 
susceptible gene associated with MEN2, located on 
chromosome 10. The RET gene encodes membrane 
tyrosine kinase receptor protein consisting of three por-
tions: extracellular, transmembrane, and intracellular 
domains. The extracellular portion is composed of four 
domains and is responsible for calcium binding, while 
intracellular portion consists of two distinct tyrosine 
kinase domains. Only one allele of the RET gene needs 
to be mutated in order to develop MEN2 syndrome. 
Morbidity in MEN2 syndrome occurs mostly because 
of chronic hypercalciuria, and to prevent this, a test 
may be performed. Nevertheless, PHPT in MEN2A is 
usually without clinical symptoms; prophylactic para-
thyroidectomy is not recommended [16].  
Single immunohistochemical markers such as parafi-
bromin and Ki-67 are among the most studied and most 
utilised, but many additional markers have been, and 
continue to be, evaluated, such as galectin-3, PGP9.5, 
Rb, bcl2, p27, hTERT, mdm2, and APC. Although not 
widely available in many laboratories, a panel of im-
munohistochemical markers may prove most useful 
as an adjunct in the evaluation of challenging para-
thyroid tumours [62].
Imaging methods
The use of imaging before performing surgery for 
patients with hyperparathyroidism is a golden stan-
dard in order to locate hyperfunctioning glands and 
determine its effect on the whole organism. Usually 
a single, adenomatous, and enlarged gland is the cause 
of primary hyperparathyroidism, so a pre-operative 
work-up should be performed because it will help 
the surgeon to plan the best surgical approach to the 
patient and it serves as a helpful guide for choos-
ing the type of operation [25]. The preoperative 
diagnostic studies may be non-invasive or invasive. 
Within non-invasive methods the following can be 
distinguished: neck ultrasound (US), single photon 
emission computed tomography (SPECT), Tc-99m 
sestamibi imaging, magnetic resonance imaging (MRI), 
four-dimensional CT scan (4-D CT), and positron 
emission tomography combined with CT scan (Tab. 1). 
Neck ultrasonography is a type of functional imaging 
method that can be used any time before or during 
surgery due to its low cost and good access. It enables 
quick localisation of the affected gland, thus decreas-
ing the extent of neck dissection [26, 27]. Subtraction 
scintigraphy Tc-99 sestamibi is also widely used. The 
latest research shows that it is essential for localisa-
tion of rapid washout parathyroid adenomas. It also 
showed that pre-operative PTH levels and the size of 
the gland where major determinants of Tc-99 sestamibi 
positivity on early-phase Tc-99m scans, and size is 
an independent factor of late-phase Tc-99m [28, 29]. 
There is a possibility to combine neck ultrasonography 
and Tc-99m sestamibi in order to increase the specific-
ity and sensitivity to over 90% [28]. If both methods 
are positive, the exact surgical approach may be deter-
mined. On the other hand, it those are negative, most 
surgeons decide to identify all glands during an open 
parathyroidectomy because cases of false negative 
scintigraphy, in patients with primary parathyroidism, 
are quite rare and usually correspond to lesions be-
yond the equipment’s resolution limit [29]. Subsequent 
imaging methods are 4D-CT scan and MRI, as more 
sophisticated and expensive radiological methods 
that can be helpful in discovering ectopic parathyroid 
glands. In most cases those methods are used in reop-
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erative cases [30] and are helpful in early distinguish-
ing of parathyroid carcinomas from other parathyroid 
lesions. Recent research showed that CT features of 
high short-to-long axis ratio, irregular shape, and the 
presence of peritumoral infiltration and calcification 
may be indicators for differentiating parathyroid 
carcinoma from benign parathyroid hyperplasia [31]. 
Radiation exposure to neck by 4D-CT is relatively high 
and its usage is limited to first investigation in order 
to diagnose of primary parathyroidism. Exposure to 
radiation should be restricted if possible, so evaluation 
of the percentage arterial enhancement as objective 
radiological index can be helpful, and used to deter-
mine parathyroid lesions (adenoma/hyperplasia) and 
discriminate it from thyroid tissue and lymph nodes 
[32]. Positron emission and computed tomography 
(PET/CT) may also be performed as a non-invasive di-
agnostic method. Parathyroid adenoma and probably 
most parathyroid hyperplasia may be exactly localised 
in patients with primary hyperparathyroidism using 
choline PET/CT. Thus, minimally invasive surgical 
intervention may be further performed with lower 
risk of complications [33, 34]. Ultrasound, Tc-99m, and 
SPECT/CT all have greater value in the diagnosis of 
parathyroid adenoma than parathyroid hyperplasia. 
Tc-99m and SPECT/CT should be optimal for detecting 
parathyroid adenoma, where early scanning is better 
than delayed scanning. In comparison, ultrasound is 
slightly better in the localisation of parathyroid hyper-
plastic lesions than Tc-99m and SPECT/CT. The best 
way to improve accuracy in localisation of parathyroid 
hyperplastic lesions is to combine ultrasonography 
with SPECT/CT or Tc-99m. This should be taken into 
consideration as a first-line diagnostic method when 
detecting parathyroid hyperplasia [35].
One of the most promising imaging techniques 
in primary hyperparathyroidism is PET/CT with 
choline-based tracers. Choline PET/CT shows favour-
able results in the detection of hyperfunctioning 
parathyroid tissue and may replace conventional 
technetium-99m-sestamibi scintigraphy using planar 
dual-phase imaging, SPECT, or SPECT/CT in preopera-
tive planning of parathyroid surgery [63]. Localisation 
of single gland adenomas can be achieved with choline 
PET/CT in 80–96% of cases. The high sensitivity and 
accuracy of choline PET/CT imaging is documented 
even in cases of repeated surgery for recurrent PHPT, 
in coexistent nodular goitre, or in the detection of ad-
enoma in atypical localisation [65]. 
Invasive methods are used usually reoperative cases 
where anatomical localisation of the affected gland is 
even more crucial and the following are distinguished: 
selective arteriography, fine needle aspiration (FNA), 
and selective venous sampling [36]. Selective arteriog-
raphy is useful because all parathyroid glands that are 
enlarged are highly vascular. Because of this fact, the 
contrast may be easily injected and visualise the affected 
glands very well. It can identify even small and ectopic 
parathyroid glands and is commonly used in combina-
tion with venous sampling methods, where thyroid 
venous plexus and thymic veins are required. This 
technique brings essential differentiation between hy-
perplasia, which exposes increased PTH within venous 
plexus bilaterally, and adenomas, which produce only 
unilateral elevated secretion of PTH [37]. All invasive 
methods are involved in higher risk of complications 
Table 2. Imaging studies. Based on [66]
Image name Sensitivity (%) Specificity (%) Main advantages Main disadvantages
Tc-99m 80–90 78–98 Minimal radiation 
Limited sensitivity if more glands than one are affected
Takes quite a long time
Does not assuredly distinguish thyroid nodule  
from parathyroid glands
Neck 
ultrasound 70–80 80–89
Quick and cheap
No radiation
May be performed before 
or during surgery
Unable to detect lesions smaller than 5 mm
Low sensitivity in substernal, retrotracheal,  
and retroesophageal glands
4-dimensional 
CT scan 60–80 85–98
More sensitive for 
smaller lesions than neck 
ultrasound
Exposure to radiation
Involves risk of application due to contrast agent
Not able to differentiate parathyroid glands from,  
for example, lymph node tissue
MRI 70–80 90–95 No radiation
Availability is very limited due to cost, time consumption, 
patients’ maintenance of metal objects inside the organism, 
and patients’ claustrophobia
Tc-99m — Tc-99m sestamibi imaging; US — ultrasound; 4-DCT — 4-dimensional computed tomography; MRI — magnetic resonance imaging
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than non-invasive methods. A suspicious tissue seen 
on imaging can also be sampled by FNA. After aspi-
ration, the content needs to be tested for PTH level. 
This method is not needed for conclusive diagnosis in 
most cases. Nevertheless, it may be helpful when the 
area of suspicion is not characteristic and is usual for 
parathyroid glands such as areas lateral to the carotid 
artery. All invasive methods involve a higher risk of 
complications than non-invasive methods. 
Treatment
Surgical treatment is considered as the only suitable 
therapy for PHPT. Parathyroidectomy is performed for 
symptomatic as well as for asymptomatic patients. Ex-
ploration of parathyroid glands should be performed 
by an experienced surgeon, preferably with the help 
of a pathomorphologist. It should be taken into con-
sideration that several clinical signs are helpful in 
predicting the existing pathology [1]. During operation, 
some critical decisions regarding further management 
need to be made, so the examination of removed tis-
sue should be examined in order to direct the further 
course of surgery. Regarding the decision of whether 
the operation is irreplaceable, consensus guidelines ex-
ist; recent ones recommend operation for asymptomatic 
patients with PHPT, who are younger than 50 years of 
age, having the following: signs of bone disorders such 
as osteoporosis, blood serum calcium level reaching 
1 mg or more than upper acceptable limits of normal 
value, creatine clearance should be lower than 60 cc per 
minute, or nephrolithiasis. There are also asymptomatic 
cases with worsening laboratory findings, which should 
also be admitted for surgery according to the procedure 
established during the third international workshop 
by the International Task Force on PHPT [38]. Usually, 
medical follow-up and performing a lot of diagnostic 
tests are quite expensive and prolonged in time, unlike 
surgery, which is more effective for asymptomatic and 
even more for symptomatic patients [38]. Nowadays, 
such surgeries are performed by experienced endo-
crine surgeons, who perform an increasing number of 
operations. Statistically, the risk of such operations is 
relatively low because people under 60 years old better 
undergo anaesthesia than prolonged drug therapy [1].
Bilateral neck exploration
Bilateral neck exploration is a traditional method of 
primary hyperparathyroidism treatment and has 
been a gold standard for decades. Here, endotracheal 
intubation is required followed by identification of 
all parathyroid glands by exploration of the central 
part of the neck. During this procedure, the surgeon 
is responsible for careful judgement of the tissue, 
which is grossly changed in appearance, and finally 
its removal. The exposure and incision are very similar 
to those used in standard thyroidectomy. The crucial 
step is performing the division in the middle thyroid 
veins, mobilisation of the thyroid lobes, and identifica-
tion of the thyroid artery together with the recurrent 
laryngeal nerve, followed by their retraction by vas-
cular slings. Afterwards, without or with incision of 
the fascia, the superior parathyroid gland is slated. In 
most cases, the upper parathyroid glands are related 
to the inferior thyroid artery, and the inferior para-
thyroid glands recline within 2 cm radius of the lower 
pole of the thyroid gland. Then, the inspection of the 
thyrothymic ligament and tracheoesophageal groove 
is required in case of occurrence of ectopic parathyroid 
glands. Ectopic glands can rarely also be found within 
the thyroid gland and carotid sheath, so those should 
also be checked. If all steps are accomplished, the 
surgeon may move on to performing the transcervical 
thymectomy. Transcervical thymectomy starts with 
localising the adenoma, followed by its ligation and 
division of the pedicles. Once it is done, it should be 
cleared from the surrounding tissue and removed. The 
diagnosis is usually confirmed by frozen section because 
differentiation between hyperplasia and adenoma is 
not an easy task. When the adenoma is excised, the 
surgeon identifies the remaining parathyroid glands 
or the ipsilateral gland in order to perform biopsy or 
frozen section investigation. If the results are normal, 
those glands do not require further procedure. A sub-
total 3.5 parathyroidectomy is recommended in the 
case of multi-glandular hyperplasia [48]. The Bilateral 
Neck Exploration technique enables the identification 
of all four parathyroid glands and further resection 
of the most enlarged and investigation of glands that 
seem not to be changed in gross appearance. The main 
disadvantages of this method are long operative time 
and prolonged post-operative hospitalisation period in 
comparison to less invasive ones. The cure rate reaches 
98%, and the morbidity is relatively low, which makes 
this procedure a golden standard in the therapy of the 
underlying cause of primary hyperparathyroidism.
Unilateral neck exploration
This technique enables a less invasive surgical approach 
for the treatment of the primary hyperparathyroidism. 
It has many advantages such as low risk for recurrent 
or persistent hyperparathyroidism and the ability to use 
local anaesthesia [39]. Unilateral neck exploration brings 
the same results as bilateral exploration but has a better 
cosmetic result and shorter operative time. On the other 
hand, there are several disadvantages of this technique, 
such as not being dependable in multi-glandular disease, 
where this approach should be taken into consideration 
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as having potential to fail [40]. This method is also re-
stricted to correct localisation, so imaging methods with 
improved modalities in order to enhance the sensitivity 
in localisation of adenoma are used. Usage of rapid in-
tra-operative intact parathyroid hormone (iPTH) assays 
are helpful in the confirmation the success of the opera-
tion when the patient is still on the table in the operating 
room [41] but still has almost 50% false positive results in 
patients with double adenoma. That may lead a surgeon 
to stop the procedure even if they should continue. 
On the other hand, 13% of false negative results may 
guide the doctor to perform often extended resections 
when there is no affected gland left. This leads to the 
conclusion that currently there is no possibility to be 
sure that all unexplored glands are not affected, but still 
Unilateral Neck Exploration has some essential advan-
tages [42]. The solution to cover diagnostic demands is 
proper pre-operative testing. The technique itself is not 
very time consuming. The patient needs to be placed in 
a supine position and has to have an extended head with 
arms by the body’s side. After usage of local or general 
anaesthetics, a 2 cm transverse incision takes place above 
the sternal notch in a skin crease. It should be done over 
the expected position of the parathyroid adenoma and 
the sternocleidomastoid muscle. Then, the strap muscles 
are dissected and separated. The thyroid lobe needs to 
be gently retracted superiorly. The affected, enlarged 
parathyroid is dissected with or without identification 
of recurrent laryngeal nerve. Afterwards, absorbable 
sutures are used to close the wound [41].
Minimally invasive parathyroidectomy 
and minimally invasive radio-guided 
parathyroidectomy
Minimally invasive parathyroidectomy is used to-
gether with a pre-operative localisation test, which 
suggests a unilateral approach. This technique is nor-
mally performed under cervical block, and for success 
determination of intra-operative iPTH is used [43]. 
There is a documented procedure of excision of even 
giant parathyroid adenoma using minimally invasive 
transcervical approach after its radiological localisation 
pre-operatively resulting in full recovery. This case leads 
to the conclusion that this method is an advantageous 
alternative for neck exploration or sternotomy [44].
Minimally invasive radio-guided parathyroidecto-
my is performed with exploitation of a gamma camera, 
which enables usage of increased sensitivity of Tc-99m 
sestamibi intra-operatively [45]. This method facilitates 
establishment of exact localisation of the affected gland 
and following its removal. Patients with a positive 
pre-operative Tc-99m sestamibi can be operated without 
general anaesthesia, which is an advantage of minimally 
invasive surgery [43]. This technique requires usage of 
a sestamibi scan (MIBI scan). If the MIBI scan is posi-
tive and shows a single pathological focus within the 
neck area, it is required to perform MIRP. Following 
this procedure, the patient needs to be re-injected up to 
60 minutes before operation [41]. Afterwards, anaesthe-
sia (local or general) should be administered and a 2-4 
cm transverse incision above sternal notch should be 
done. The localised affected gland is then dissected and 
removed. The last step is comparison of measured ex 
vivo activity and neck activity after excision. When the 
value is over 20%, it is an indication for surgery termina-
tion. The risk of occurrence of possible complications is 
very low and the overall cost of this technique is also 
lower in comparison to more invasive methods. Other 
advantages may be distinguished, such as short time 
of patient recovery, short operative time, and shorter 
hospitalisation [43]. The gamma probe-assisted pro-
cedure is also very useful in the excision of an ectopic 
parathyroid adenoma located within the thymus [46].
Endoscopic parathyroidectomy 
Endoscopic surgeries are now the most common type of 
procedure worldwide due to their many advantages. Be-
cause it is used for the operation of parathyroid glands, 
it leaves the best cosmetic result offering a good and safe 
approach to deep and ectopic locations. The proper mag-
nification should be used within this method so that it 
decreases the risk of intra-operative injury. Nevertheless, 
the general anaesthesia must be used, and the operating 
time is longer. Moreover, this method may be success-
fully used in complicated cases, such as retroesophageal 
parathyroid adenoma coexisting with an aberrant right 
subclavian artery [47]. During endoscopic parathy-
roidectomy the patient needs to be placed in a supine 
position. The neck remains positioned neutrally. After 
general anaesthesia is introduced, a 5 mm incision has 
to be made above the sternal notch followed by carbon 
monoxide insufflation to 10 mmHg. Using a 5 mm 0° 
endoscope, dissection of the subplatysmal plane to-
wards the side of the localised adenoma is performed 
followed by usage of a 30° endoscope in order to place 
three ports in the lateral side of the neck. The dissection 
is performed laterally to the strap muscles and medially 
to the carotid artery until meeting the gland and identi-
fying the recurrent laryngeal nerve. After the dissection 
of the gland, the ligation of the vascular pedicle with 
an ENDOLOOP is performed followed by its removal 
in a bag through the 5 mm port. Closure of the wound 
is possible by using Steri-Strips [41].
Surgical approach to ectopic mediastinal 
parathyroid adenoma
Ectopic adenomas are not located next to the thyroid 
gland and can cause problems with its localisation, even 
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for experienced surgeons. The occurrence of ectopic 
adenomas is quite rare and occur in 3-4% of all parathy-
roid adenoma cases [49]. Primary hyperparathyroidism 
caused by an ectopic mediastinal parathyroid adenoma 
is not very common either. Most abnormal parathyroid 
glands are localised in the superior mediastinum and 
can be removed by a cervical incision. However, there 
are cases when those glands are hard or impossible to 
access using traditional methods such as median ster-
notomy or thoracotomy [50]. Over the last decade, we 
saw significant technical advancements in detection 
and resection of affected glands using video-assisted 
thoracoscopic surgery (VATS). It is a modern alternative 
to median sternotomy, which was used for many years 
in cases where adenoma was not accessible through 
the neck. Video-assisted thoracoscopic surgery may 
be performed with subxiphoid and lateral thoracic ap-
proach. The latest studies showed that single-incision 
mediastinal tumour resection by subxiphoid access is 
a useful endoscopic surgical approach for the treatment 
of mediastinal ectopic parathyroid adenomas. The 
post-thoracotomy pain syndrome is limited, and the 
aesthetic outcomes are protreptic [51]. Most patients 
undergoing VATS do not suffer from serious complica-
tions, but some may require conversion to median ster-
notomy for thymoma removal in cases of false positive 
pre-operative imaging. However, with the appropriate 
radiological preparation before the procedure, VATS is 
an effective and safe approach to ectopic mediastinal 
parathyroid adenoma [52]. Moreover, this method may 
be used in complicated cases, such as retroesophageal 
parathyroid adenoma coexisting with an aberrant right 
subclavian artery. This approach is also useful when the 
parathyroid glands are in the posterior mediastinum 
or among adipose tissue very close to the diaphragm. 
Unfortunately, surgeons dealing with the treatment of 
primary hyperparathyroidism rarely have skills in tho-
racic surgery techniques, and, conversely, thoracic sur-
geons have exceptional contact with these patients. All 
this affects the ability to search for parathyroid glands 
and has a direct relationship to the results of surgery.
In preparation for VATS, it is worth performing 
Tc-99m sestamibi scintigraphy and endobronchial 
ultrasound biopsy. Because Tc(99) sestamibi reveals 
the localisation of an intense intake, endobronchial 
ultrasound-guided transbronchial needle aspiration 
(EBUS-TBNA) can be essential for diagnosis confirma-
tion [53]. After surgery, it is still essential to measure the 
blood serum calcium levels because hypocalcaemia is 
seen with increasing frequency and occurs in about 30% 
of cases [54]. In such cases it requires oral supplementa-
tion with calcium, and in several cases together with 
activated vitamin D [56]. Patients who were suffering 
from hypercalcaemia and high PTH levels before sur-
gery are at higher risk of transient hypoparathyroidism 
because of port-operative transient low blood serum 
calcium levels resulting from suppression of remaining 
parathyroid glands. Permanent hypercalcaemia also oc-
curs as an outcome of removal and devascularisation of 
functioning glands but is quite rare [57]. The resection of 
parathyroid glands is the best therapy for PHPT. It has 
important outcomes such as correction of biochemical 
values, improvement of life quality, and lowering the 
bone fracture risk [55, 58].
Conclusion
Primary hyperparathyroidism is one of the main causes 
of hypercalcaemia in patients, who are usually diag-
nosed before clinically significant symptoms develop 
due to blood tests performed as preventive care or in 
order to diagnose some other disorders. Nevertheless, 
classical symptoms are related to abnormal function of 
parathyroid glands, resulting in elevated blood calcium 
levels, leading to disturbances of psychological func-
tioning as well to disorders regarding urinary tract, and 
the gastrointestinal and central nervous system. The 
largest group of patients diagnosed with the PHPT are 
those around 55 years of age. The diagnosis is mainly 
based on measuring the level of calcium and PTH in 
blood, giving a guidepost to perform surgery, which, 
if there are no contraindications, is the most effective 
form of therapy with very low consumption of time 
and risk of recurrence.
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